Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Europe's main stock index logged its best day in six weeks on Monday, with defence stocks in the lead on prospects of higher ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...